We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+5.2%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$250M
AUM Growth
+$56M
Cap. Flow
+$44.7M
Cap. Flow %
17.87%
Top 10 Hldgs %
51.39%
Holding
108
New
15
Increased
21
Reduced
34
Closed
11

Top Buys

Rank Stock Value
1
AMZN icon
Amazon
AMZN
+$3.19M
2
MU icon
Micron Technology
MU
+$1.73M
3
C icon
Citigroup
C
+$1.45M
4
URNM icon
Sprott Uranium Miners ETF
URNM
+$1.1M
5
AMGN icon
Amgen
AMGN
+$818K

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$2.95M
2
AAPL icon
Apple
AAPL
+$2.23M
3
RVNC
Revance Therapeutics, Inc.
RVNC
+$1.15M
4
GLD icon
SPDR Gold Trust
GLD
+$916K
5
BHVN icon
Biohaven
BHVN
+$805K

Sector Composition

Rank Sector Weight
1 Healthcare 26.92%
2 Technology 16.18%
3 Communication Services 7.16%
4 Consumer Discretionary 6.33%
5 Financials 3.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORCL icon
51
PUT
Oracle
ORCL
$374B
$1.02M 0.41%
+6,000
New +$869K
ZLAB icon
52
Zai Lab
ZLAB
$2.06B
$1.02M 0.41%
42,250
+11,800
+39% +$223K
PFE icon
53
Pfizer
PFE
$143B
$994K 0.4%
34,350
-900
-3% -$26.3K
OI icon
54
O-I Glass
OI
$1.1B
$974K 0.39%
74,250
-16,500
-18% -$198K
STEW
55
SRH Total Return Fund
STEW
$1.79B
$932K 0.37%
59,000
– –
GDXJ icon
56
VanEck Junior Gold Miners ETF
GDXJ
$6.89B
$927K 0.37%
19,000
+5,300
+39% +$244K
MRVL icon
57
Marvell Technology
MRVL
$168B
$902K 0.36%
12,500
-5,000
-29% -$345K
AVGO icon
58
Broadcom
AVGO
$1.85T
$863K 0.34%
5,000
-4,750
-49% -$762K
EVO icon
59
Evotec
EVO
$679M
$792K 0.32%
217,055
+102,102
+89% +$405K
BNED icon
60
Barnes & Noble Education
BNED
$431M
$782K 0.31%
84,500
+7,000
+9% +$72.2K
PYPL icon
61
PayPal
PYPL
$48.9B
$780K 0.31%
10,000
-1,000
-9% -$66.9K
BUR icon
62
Burford Capital
BUR
$903M
$690K 0.28%
52,000
– –
SNY icon
63
Sanofi
SNY
$103B
$634K 0.25%
11,000
– –
BA icon
64
Boeing
BA
$171B
$631K 0.25%
4,150
-500
-11% -$85.7K
TEVA icon
65
CALL
Teva Pharmaceuticals
TEVA
$40.8B
$604K 0.24%
33,500
+18,500
+123% +$324K
GDX icon
66
PUT
VanEck Gold Miners ETF
GDX
$22.7B
$597K 0.24%
+15,000
New +$568K
FLUT icon
67
Flutter Entertainment
FLUT
$18.1B
$593K 0.24%
2,500
-700
-22% -$145K
EEM icon
68
iShares MSCI Emerging Markets ETF
EEM
$28.8B
$573K 0.23%
12,500
– –
NAMS icon
69
NewAmsterdam Pharma
NAMS
$3.25B
$564K 0.23%
+34,000
New +$588K
AMZN icon
70
CALL
Amazon
AMZN
$2.92T
$559K 0.22%
3,000
– –
BIDU icon
71
PUT
Baidu
BIDU
$37.7B
$526K 0.21%
+5,000
New +$442K
TDOC icon
72
Teladoc Health
TDOC
$1.22B
$482K 0.19%
52,500
– –
ARQ icon
73
Arq
ARQ
$84.6M
$429K 0.17%
73,000
+51,000
+232% +$311K
RPRX icon
74
Royalty Pharma
RPRX
$25.9B
$424K 0.17%
+15,000
New +$415K
BIDU icon
75
CALL
Baidu
BIDU
$37.7B
$421K 0.17%
+4,000
New +$353K
1 2
3
4 5

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q3 2024 Portfolio in Review

As of Q3 2024, DCF Advisers held 108 positions worth $250M, up 29% from $194M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DCF Advisers deployed $44.7M of net new capital in Q3 2024, opening 15 new positions and adding to 21 existing holdings. Its largest new stake was NewAmsterdam Pharma: 34,000 shares worth $564K.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 34% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $2.95M trimmed.

  • DCF Advisers's largest Q3 2024 buy was NewAmsterdam Pharma: 34,000 shares worth $564K.
  • DCF Advisers added most to Amazon in Q3 2024, an estimated $3.19M increase.
  • DCF Advisers's biggest Q3 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $2.95M.
  • DCF Advisers fully exited Snowflake in Q3 2024, selling an estimated $439K.
  • DCF Advisers's ten largest holdings make up 51% of its $250M portfolio in Q3 2024.
  • DCF Advisers opened 15 new positions and closed 11 in Q3 2024.
  • DCF Advisers's portfolio value rose 29% quarter-over-quarter to $250M.

Based on DCF Advisers's 13F filing for Q3 2024, filed 13 Nov 2024.